Merdury Biopharmaceutical Corporation (TPEX:6932)

Merdury Biopharmaceutical Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	80.49	53.17	68.01	44.29	31.94	2.56
Short-Term Investments	56	110.6	162.8	284.78	108.7	-
Cash & Short-Term Investments	136.49	163.77	230.81	329.07	140.64	2.56
Cash Growth	-31.38%	-29.05%	-29.86%	133.99%	5391.45%	2877.91%
Other Receivables	6.47	6.38	4.73	0.23	2.46	-
Receivables	6.47	6.38	4.73	0.23	2.46	-
Prepaid Expenses	6.43	4.25	7.18	10.07	2.64	-
Other Current Assets	0.36	0.36	0.18	0.55	-	1.37
Total Current Assets	151.97	174.76	242.9	339.93	145.73	3.93
Property, Plant & Equipment	89.84	89.75	94.41	79.94	75.15	8.46
Other Intangible Assets	4.71	5.45	4.53	2.71	0.5	0.49
Other Long-Term Assets	13.37	8.44	11.37	15.5	8.55	0.51
Total Assets	259.89	278.39	353.2	438.08	229.93	13.38

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accrued Expenses	5.13	7.99	7.21	-	4.61	0.66
Current Portion of Long-Term Debt	2.14	2.12	1.21	-	-	-
Current Portion of Leases	1.13	0.73	2.6	0.68	1.05	0.79
Current Unearned Revenue	5.79	5.79	5.48	0.44	-	-
Other Current Liabilities	3.46	3.14	2.73	6.93	1.57	0.26
Total Current Liabilities	19.58	19.77	19.24	8.05	7.23	1.7
Long-Term Debt	37.02	38.1	40.39	41.6	41.6	-
Long-Term Leases	2.52	0.85	3.31	0.07	0.77	1.22
Total Liabilities	59.12	58.72	62.93	49.72	49.6	2.93

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	108.15	106.74	105.46	103.99	100.87	15.4
Additional Paid-In Capital	179.77	244.5	291.29	328.17	110.72	0.37
Retained Earnings	-22.71	-67.23	-50.57	-43.82	-31.25	-5.31
Treasury Stock	-64.81	-64.81	-56.24	-	-	-
Comprehensive Income & Other	0.37	0.46	0.33	0.01	-	-
Shareholders' Equity	200.77	219.67	290.27	388.35	180.33	10.46
Total Liabilities & Equity	259.89	278.39	353.2	438.08	229.93	13.38

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	42.8	41.79	47.51	42.35	43.42	2.01
Net Cash (Debt)	93.69	121.98	183.3	286.73	97.21	0.55
Net Cash Growth	-38.39%	-33.45%	-36.07%	194.94%	17575.09%	-
Net Cash Per Share	0.22	0.29	0.44	0.72	0.26	0.00
Filing Date Shares Outstanding	427.65	422.03	421.85	415.96	403.46	403.46
Total Common Shares Outstanding	427.65	422.03	421.85	415.96	403.46	307.94
Working Capital	132.39	154.99	223.66	331.88	138.5	2.22
Book Value Per Share	0.47	0.52	0.69	0.93	0.45	0.03
Tangible Book Value	196.07	214.22	285.75	385.65	179.83	9.97
Tangible Book Value Per Share	0.46	0.51	0.68	0.93	0.45	0.03
Land	41.9	41.9	41.9	-	41.9	-
Buildings	18.2	18.2	18.27	-	18.12	-
Machinery	35.01	34.42	23.45	-	6.42	5.88
Construction In Progress	8.52	7.29	11.59	-	7.5	-
Leasehold Improvements	1.18	2.36	2.33	-	0.91	0.91

Data Source: S&P Global Market Intelligence Last updated: Aug 13, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 7, 2026

Data Sources Report a data error